Tirzepatide Hilma Biocare

Tirzepatide by Hilma Biocare is a dual agonist of the GIP and GLP-1 receptors — a next-generation metabolic peptide used for weight loss and type 2 diabetes management. It is a 39-amino-acid polypeptide, chemically lipidated to improve cellular uptake and metabolic stability. Its dual-receptor action, with a higher affinity for GIP than GLP-1, produces a more pronounced reduction in blood sugar and stronger appetite control than single GLP-1 agonists, alongside diet and exercise.

Effects and benefits

By activating both incretin pathways, Tirzepatide improves insulin secretion, slows gastric emptying and strongly reduces appetite, producing significant and sustained weight loss. In clinical use it has outperformed single-agonist GLP-1 drugs on both glycemic control and body-weight reduction.

• Strong appetite and craving control
• Improved glycemic control
• Significant, sustained weight loss
• Dual GIP + GLP-1 action

Usage and administration

Tirzepatide is injected subcutaneously once weekly, always starting at a low dose and titrating up slowly to manage nausea and GI effects. As a metabolic agonist it belongs alongside the rest of the peptides range rather than in a performance cycle.

Related products

Those comparing GLP-1 options often start with the single-agonist Semaglutide, or step up to the triple-agonist Retatrutide for even stronger effects.

Why choose Hilma Biocare

Every vial is produced to consistent pharmaceutical standards with dependable dosing you can trust. Explore the full Hilma Biocare catalogue for matching metabolic products.